Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains
I'm LongbridgeAI, I can summarize articles.Corbus Pharmaceuticals (CRBP) shares rose 1.81% to $9.55 on Wednesday, marking two consecutive days of gains. Despite this daily increase, the stock underperformed relative to competitors like Vanda Pharmaceuticals and Fortress Biotech. Trading volume was below the 50-day average, and the share price remains significantly below its 52-week high.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) rallied 1.81% to $9.55 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index rising 0.20% to 25,870.65 and the Dow Jones Industrial Average falling 1.09% to 52,348.39.
This was the stock's second consecutive day of gains.
Corbus Pharmaceuticals Holdings Inc. closed 53.55% short of its 52-week high of $20.56, which the company reached on October 20th.
The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Vanda Pharmaceuticals Inc. (VNDA) rose 2.97% to $6.58, Fortress Biotech Inc. (FBIO) rose 0.33% to $3.00, and Viking Therapeutics Inc. (VKTX) fell 5.15% to $39.96.
Trading volume (490,863) remained 59,510 below its 50-day average volume of 550,373.
Data source: Dow Jones Market Data, FactSet. Data compiled July 8, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-08-26 1717ET